LineaGen, Inc
Salt Lake City, UT · Founded 2006 · CIK 0001415979 · Biotech · Acquired
Clinical genetic testing and analysis platform for identifying genetic causes of neurodevelopmental disorders
bionanolaboratories.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $38M
- 6 Form D · Jan 2015
- 140 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 32
- 0 granted · 32 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2009201020112012201320142015
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,100,000 | |
| Private capital raised | Form D · SEC | $5,012,787 | |
| Private capital raised | Form D · SEC | $3,600,000 | |
| Private capital raised | Form D · SEC | $150,000 | |
| Private capital raised | Form D · SEC | $16,107,915 | |
| Private capital raised | Form D · SEC | $12,173,420 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2262 | HEMATHERIX LLC | — | — |
| 2263 | TACIT THERAPEUTICS, INC. | — | — |
| 2264 | SOTERIA SYSTEMS, INC. | — | $2.7M |
| 2265 | LineaGen, Inc | — | $38M |
| 2266 | GPER G-1 Development Group LLC | — | — |
| 2267 | VIROGENICS, INC. | — | — |
| 2268 | PRODIGY BIOTECH, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Burt De MillExecutive Officer
- Lisa DunleaDirector
- Michael FitzgeraldDirector
- Al HarrisDirector
- Michael JerstadDirector
- David KabakoffDirector
- Fred MiddletonDirector
- Gayland MoffatExecutive Officer
- Dinesh PatelDirector
- Michael PaulDirector · Executive Officer
- Stephen PrescottDirector
- Mary TannerDirector
- Michael WalshDirector
- Marc WhiteExecutive Officer
- Daniel WoodDirector
Patents
- Genetic Markers Associated With Asd And Other Childhood Developmental Delay Disordersapplication
- Genetic Markers Associated With Asd And Other Childhood Developmental Delay Disordersapplication
- Diagnosis And Prediction Of Autism Spectrum Disorderapplication
- Identification Of Seizure Susceptibility Region In Wolf-hirschhorn Syndrome And Treatment Thereofapplication
- Genetic Markers Associated With Asd And Other Childhood Developmental Delay Disordersapplication
- Diagnosis And Prediction Of Autism Spectrum Disorderapplication
- Identification Of Seizure Susceptibility Region In Wolf-hirschhorn Syndrome And Treatment Thereofapplication
- Apparatus, Compositions, and Methods for Assessment of Chronic Obstructive Pulmonary Disease Progression Among Rapid and Slow Decline Conditionsapplication
- Risk Factors of Cigarette Smoke-Induced Spriometric Phenotypesapplication
- Methods For Identification And Prediction Of Multiple Sclerosis Disease And Therapy Responseapplication
- Diagnosis And Prediction Of Autism Spectrum Disorderapplication
- Genetic Markers Associated With Asd And Other Childhood Developmental Delay Disordersapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.